MADRIGAL PHARMACEUTICALS, INC. Net Income
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Net Income of -$57.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$57.94M.
- MADRIGAL PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$94.39M.
- MADRIGAL PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$58.58M.
- MADRIGAL PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$114.19M.
- MADRIGAL PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2020 was -$202.24M.
- MADRIGAL PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2019 was -$83.95M.
- MADRIGAL PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2018 was -$32.81M.
- MADRIGAL PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2017 was -$31.15M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$57.94M 10-Q · filed 2026-07-30 | -$152.33M 10-Q · filed 2026-07-30 | -$210.91M derived: sum of 3 quarters · filed 2026-07-30 | -$325.10M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | -$94.39M 10-Q · filed 2026-07-30 | -$152.97M derived: sum of 2 quarters · filed 2026-07-30 | -$267.16M derived: sum of 3 quarters · filed 2026-07-30 | -$309.44M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | -$58.58M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$172.76M derived: sum of 2 quarters · filed 2026-04-28 | -$215.05M derived: sum of 3 quarters · filed 2026-07-30 | -$288.28M DEF 14A · filed 2026-04-28 | |
| 2025-09-30 | -$114.19M 10-Q · filed 2025-11-04 | -$156.47M derived: sum of 2 quarters · filed 2026-07-30 | -$229.71M 10-Q · filed 2025-11-04 | -$289.13M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | -$42.28M 10-Q · filed 2026-07-30 | -$115.52M 10-Q · filed 2026-07-30 | -$174.94M derived: sum of 3 quarters · filed 2026-07-30 | -$281.90M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | -$73.24M 10-Q · filed 2026-07-30 | -$132.65M derived: sum of 2 quarters · filed 2026-07-30 | -$239.62M derived: sum of 3 quarters · filed 2026-07-30 | -$391.59M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2024-12-31 | -$59.42M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$166.38M derived: sum of 2 quarters · filed 2026-04-28 | -$318.35M derived: sum of 3 quarters · filed 2026-04-28 | -$465.89M DEF 14A · filed 2026-04-28 | |
| 2024-09-30 | -$106.96M 10-Q · filed 2025-11-04 | -$258.94M derived: sum of 2 quarters · filed 2025-11-04 | -$406.48M 10-Q · filed 2025-11-04 | -$518.67M derived: sum of 4 quarters · filed 2025-11-04 | |
| 2024-06-30 | -$151.97M 10-Q · filed 2025-11-04 | -$299.51M 10-Q · filed 2025-08-05 | -$411.71M derived: sum of 3 quarters · filed 2025-11-04 | -$510.45M derived: sum of 4 quarters · filed 2025-11-04 | |
| 2024-03-31 | -$147.54M 10-Q · filed 2025-11-04 | -$259.74M derived: sum of 2 quarters · filed 2025-11-04 | -$358.48M derived: sum of 3 quarters · filed 2025-11-04 | -$444.27M derived: sum of 4 quarters · filed 2025-11-04 | |
| 2023-12-31 | -$112.19M 10-K · filed 2024-02-28 | -$210.93M derived: sum of 2 quarters · filed 2024-10-31 | -$296.73M derived: sum of 3 quarters · filed 2024-10-31 | -$373.63M DEF 14A · filed 2026-04-28 | |
| 2023-09-30 | -$98.74M 10-Q · filed 2024-10-31 | -$184.54M derived: sum of 2 quarters · filed 2024-10-31 | -$261.44M 10-Q · filed 2024-10-31 | -$347.34M derived: sum of 4 quarters · filed 2024-10-31 | |
| 2023-06-30 | -$85.80M 10-Q · filed 2024-10-31 | -$162.70M 10-Q · filed 2024-08-07 | -$248.60M derived: sum of 3 quarters · filed 2024-10-31 | -$329.80M derived: sum of 4 quarters · filed 2024-10-31 | |
| 2023-03-31 | -$76.90M 10-Q · filed 2024-10-31 | -$162.80M derived: sum of 2 quarters · filed 2024-10-31 | -$244.00M derived: sum of 3 quarters · filed 2024-10-31 | -$314.73M derived: sum of 4 quarters · filed 2024-10-31 | |
| 2022-12-31 | -$85.91M 10-K · filed 2024-02-28 | -$167.10M derived: sum of 2 quarters · filed 2024-02-28 | -$237.83M derived: sum of 3 quarters · filed 2024-02-28 | -$295.25M DEF 14A · filed 2026-04-28 | -$295.35M 10-K · filed 2023-02-23 |
| 2022-09-30 | -$81.20M 10-K · filed 2024-02-28 | -$151.93M derived: sum of 2 quarters · filed 2024-02-28 | -$209.44M 10-Q · filed 2023-11-06 | -$273.99M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | -$70.73M 10-K · filed 2024-02-28 | -$128.25M 10-Q · filed 2023-08-08 | -$192.80M derived: sum of 3 quarters · filed 2024-02-28 | -$255.90M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | -$57.52M 10-K · filed 2024-02-28 | -$122.07M derived: sum of 2 quarters · filed 2024-02-28 | -$185.17M derived: sum of 3 quarters · filed 2024-02-28 | -$246.82M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | -$64.55M 10-K/A · filed 2023-03-03 | -$127.65M derived: sum of 2 quarters · filed 2023-03-03 | -$189.30M derived: sum of 3 quarters · filed 2023-03-03 | -$241.85M DEF 14A · filed 2026-04-28 | |
| 2021-09-30 | -$63.10M 10-K/A · filed 2023-03-03 | -$124.75M derived: sum of 2 quarters · filed 2023-03-03 | -$177.30M 10-Q · filed 2022-11-03 | -$236.42M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2021-06-30 | -$61.65M 10-K/A · filed 2023-03-03 | -$114.20M 10-Q · filed 2022-08-04 | -$173.32M derived: sum of 3 quarters · filed 2023-03-03 | -$231.28M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2021-03-31 | -$52.55M 10-K/A · filed 2023-03-03 | -$111.67M derived: sum of 2 quarters · filed 2023-03-03 | -$169.63M derived: sum of 3 quarters · filed 2023-03-03 | -$218.66M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2020-12-31 | -$59.12M 10-K · filed 2022-02-24 | -$117.09M derived: sum of 2 quarters · filed 2022-02-24 | -$166.11M derived: sum of 3 quarters · filed 2022-02-24 | -$202.24M 10-K/A · filed 2023-03-03 | |
| 2020-09-30 | -$57.96M 10-K · filed 2022-02-24 | -$106.99M derived: sum of 2 quarters · filed 2022-02-24 | -$143.12M 10-Q · filed 2021-11-04 | -$170.86M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | -$49.02M 10-K · filed 2022-02-24 | -$85.16M 10-Q · filed 2021-08-05 | -$112.90M derived: sum of 3 quarters · filed 2022-02-24 | -$134.33M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | -$36.13M 10-K · filed 2022-02-24 | -$63.88M derived: sum of 2 quarters · filed 2022-02-24 | -$85.30M derived: sum of 3 quarters · filed 2022-02-24 | -$105.00M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | -$27.74M 10-K · filed 2021-02-25 | -$49.17M derived: sum of 2 quarters · filed 2021-02-25 | -$68.87M derived: sum of 3 quarters · filed 2021-02-25 | -$83.95M 10-K · filed 2022-02-24 | |
| 2019-09-30 | -$21.43M 10-K · filed 2021-02-25 | -$41.13M derived: sum of 2 quarters · filed 2021-02-25 | -$56.21M 10-Q · filed 2020-11-05 | -$67.68M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | -$19.70M 10-K · filed 2021-02-25 | -$34.78M 10-Q · filed 2020-08-06 | -$46.25M derived: sum of 3 quarters · filed 2021-02-25 | -$54.77M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$15.08M 10-K · filed 2021-02-25 | -$26.55M derived: sum of 2 quarters · filed 2021-02-25 | -$35.07M derived: sum of 3 quarters · filed 2021-02-25 | -$41.53M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | -$11.47M 10-K · filed 2020-02-26 | -$19.99M derived: sum of 2 quarters · filed 2020-02-26 | -$26.45M derived: sum of 3 quarters · filed 2020-02-26 | -$32.81M 10-K · filed 2021-02-25 | |
| 2018-09-30 | -$8.51M 10-K · filed 2020-02-26 | -$14.97M derived: sum of 2 quarters · filed 2020-02-26 | -$21.34M 10-Q · filed 2019-11-06 | -$29.78M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-06-30 | -$6.46M 10-K · filed 2020-02-26 | -$12.82M 10-Q · filed 2019-08-07 | -$21.27M derived: sum of 3 quarters · filed 2020-02-26 | -$29.63M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-03-31 | -$6.36M 10-K · filed 2020-02-26 | -$14.81M derived: sum of 2 quarters · filed 2020-02-26 | -$23.17M derived: sum of 3 quarters · filed 2020-02-26 | -$31.52M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2017-12-31 | -$8.45M 10-K · filed 2019-02-27 | -$16.81M derived: sum of 2 quarters · filed 2019-02-27 | -$25.16M derived: sum of 3 quarters · filed 2019-02-27 | -$31.15M 10-K · filed 2020-02-26 | |
| 2017-09-30 | -$8.36M 10-K · filed 2019-02-27 | -$16.71M derived: sum of 2 quarters · filed 2019-02-27 | -$22.71M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | -$8.35M 10-K · filed 2019-02-27 | -$14.35M 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | -$6.00M 10-K · filed 2019-02-27 | ||||
| 2016-12-31 | -$26.39M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |